ATHX News and Press, Athersys Inc.

2023-11-17 06:28:55 ET More on Athersys Athersys crashes after bankruptcy warning Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information for Athersys For further details see: Athersys GAAP EPS o...

Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

2023-11-09 18:00:54 ET More on Athersys Athersys crashes after bankruptcy warning Athersys shares slide on pricing $3.5 million stock offering Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information ...

Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...

2023-10-11 07:23:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Wednesday morning and we’re covering all of the latest news investors need to know about! Moving stocks this morning are study results, ban...

2023-10-10 12:13:05 ET Nano-cap biotech Athersys ( NASDAQ: ATHX ) fell ~50% on Tuesday after the developer of MultiStem cell therapy warned about a potential bankruptcy filing following a setback in a Phase 3 trial for the candidate. Cleveland, Ohio-based Athersys ( ATHX ...

The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces that the independent data safe...

Athersys, Inc. (Nasdaq: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC ® ) technology for equine, canine, and feline health applications, announces the s...

2023-10-02 17:17:30 ET More on Athersys Athersys shares slide on pricing $3.5 million stock offering Seeking Alpha’s Quant Rating on Athersys Historical earnings data for Athersys Financial information for Athersys For further details see: ...